medigraphic.com

2021, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2021; 22 (2)

Characteristics of some humoral and cellular immunity´s parameters in patients with lymphedema

Maldonado VK, Rodríguez VLE, Mahía VM

Language: Spanish
References: 25
Page: 1-15
PDF size: 561.80 Kb.


ABSTRACT

Introduction: Lymphedema is a chronic disease with a negative impact on the health of patients with lymphedema. It is considered an underestimated and sub-recorded health problem, which requires greater research and health efforts.
Objective: Identify the characteristics of some parameters of humoral and cellular immunity in patients with lymphedema from Cerro municipality.
Methods: A descriptive study was carried out in 48 patients living in Cerro municipality, who were attended in the external consultation of the National Institute of Angiology and Vascular Surgery in the period 2011-2015. The group was divided into 24 patients with lymphedema and 24 patients without the disease. The concentrations of immunoglobulins (A, G and M) and C-reactive protein were quantified in all of them. The test of delayed hypersensitivity was also perfomed. Non-parametric chi-square was used to associate immune state with the presence of lymphedema, etiology and lymphedema stages. Reliability was of 95% (p<0.05).
Results: Female patients predominated (58.3%) and those of 60 years and older (29.2%). There was a higher frequency of recurrent lymphangitis (70.8%), predominantly stage II b secondary lymphedema (45.8%); lower right limb involvement (45.8%), with a significant difference of immunoglobulins (IgA and IgG); and frequency of anergic patients (91.7%), with positive C-reactive protein (45.8%).
Conclusions: Patients with lymphedema have their immune system affected, more frequently the anergic ones, a decrease of IgA and IgG immunoglobulins, and positivity of C-reactive protein.


REFERENCES

  1. Abbas AK, Lichtman AH, Pillai S. Inmunología celular y molecular. 6 Ed. EE.UU.: Elsevier Saunder; 2011 [acceso 27/02/2019]. Disponible en: http://www.el12cirujano.blogspot.com

  2. Liao S, von der Weid PY. Lymphatic system: An active pathway for immune protection. Semin Cell ÇDev Biol. 2015;38:83-9. DOI: https://doi.org/10.1016/j.semcdb.2014.11.012

  3. Kataru RP, Baik JE, Park HY, Wiser I, Rehal S, Shin JY. Regulation of immune function by the lymphatic system in lymphedema. Frontiers in Immunology. 2019 [acceso 10/06/2020];10:1-10. DOI: https://doi.org/10.3389/fimmu.2019.00470

  4. Ciucci JL. 6to Consenso Latinoamericano para el tratamiento del Linfedema: Guía de tratamiento. Buenos Aires: Ed. Nayarit; 2017 [acceso 22/01/2019]. Disponible en: Disponible en: http://www.centrociucci.com.ar/descargas/6-Consenso-2017-nuevo3.pdf

  5. Mahía Vilas M. El sistema inmune en los linfedemas y linfangitis de los miembros inferiores. Rev Cubana Angiol Cir Vasc. 2016 [acceso 27/02/2019];17(2):150-60. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S168200372016000200005&lng=es

  6. Nathan D, Lawson A. New conserved player in lymphatic morphogenesis. Cir Res. 2017 [acceso 27/02/2019];120(8):1216-8. Disponible en: https://www.ahajournals.org/doi/full/10.1161/circresaha.117.310861

  7. Randolph GJ, Ivanov S, Zinselmeyer BH, Scallan JP. The lymphatic system. Ann Rev Immunol. 2017 [acceso 22/06/2019];35:31-52. Disponible en: https://www.annualreviews.org/doi/abs/10.1146/annurev-immunol041015-055354

  8. Rodríguez Villalonga LE, Seuc Jo HA, Victoria García-Viniegra CR, Pérez Leonard D, Díaz Chirino L. Enfermedades y eventos asociados al linfedema en el municipio Cerro. Rev Cubana AngiolCirVasc. 2013 [acceso 02/03/2020];14(2). Disponible en: http://bvs.sld.cu/revistas/ang/vol14_2_13/ang02213.htm

  9. Qi S, Pan J. Cell-based therapy for therapeutic lymphangiogenesis. Stem Cells Dev. 2015 Feb1; 24(3):271-83. DOI: https://doi.org/10.1089/scd.2014.0390.

  10. Ulvmar MH, Mäkinen T. Heterogeneity in the lymphatic vascular system and its origin. Cardiovasc Res. 2016;111(4):310-21. DOI: https://doi.org/10.1093/cvr/cvw175

  11. Organización Mundial de la Salud (OMS). Enfermedades tropicales desatendidas: prevención, control, eliminación y erradicación. Informe de la Secretaría. OMS; 2016 [acceso 22/01/2019]. Disponible en: http://apps.who.int/iris/handle/10665/150927

  12. Rodríguez Villalonga LE, Seuc Jo AH, Lauzán Díaz E, García Lazo G, Rodríguez Álvarez M, Macías Zabuqué M. Linfedema en el municipio Cerro. Rev Cubana Angiol y Cir Vasc. 2012 [acceso 12/12/2019];13(2): Disponible en: bvs.sld.cu/revistas/ang/vol 13-2-12/ang 03212.htm

  13. Vignes S. Linfedemas de los miembros. EMC-Dermatología. 2017 Jun 1;51(2):1-3. DOI: https://doi.org/10.1016/S1761-2896(17)84298-9

  14. Mahía Vilas M. Factores psicosocio-inmunogeneticos en pacientes diabéticos con complicaciones vasculares. Rev Cubana Angiol Cir Vasc. 2017 [acceso 21/07/2019];18(1). Disponible en: http://revangiologia.sld.cu/index.php/ang/article/view/242/207

  15. Lomonte B. Nociones de Inmunología. Quinta Edición; 2018. [acceso 20/06/2020]. Disponible en: https://www.researchgate.net/publication/328628154_Nociones_de_Inmunologia_5_Ed

  16. Pérez Martin OG, Vega García IG. Capítulo XII. Dinámica de la respuesta inmune como ley principal de la inmunología. En: Inmunología en el humano. La Habana: Editorial Ciencias Médicas; 2017 [acceso 20/06/2020]. Disponible en: Disponible en: http://www.bvs.sld.cu/libros/inmunologia_humano_sano/inmunologia_humano_completo.pdf

  17. Mahía Vilas M, Cruz Lara C, Rodríguez Villalonga LE, Arpajón Peña Y. Algunos indicadores de la inmunidad celular y humoral en pacientes con linfangitis. Rev Cubana Angiol Cir Vasc. 2019 [acceso 03/07/2020];20(3). Disponible en: http://revangiologia.sld.cu/index.php/ang/article/view/80/147#ff1_80

  18. Zieske AW, Tracy RP, McMahan CA, Herderick EE, Homma S, Malcom G, et al. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1237-43. DOI: https://doi.org/10.1161/01.ATV.0000164625.93129.64

  19. Ross R. Atherosclerosisan inflammatory disease. N Engl J Med 1999; 340:115-26. DOI: https://doi.org/10.1056/NEJM19990114340020720

  20. Park SI, Yang EJ, Kim DK, Jeong HJ, Kim GC, Sim YJ. Prevalence and epidemiological factors involved in cellulitis in Korean patients with lymphedema. Ann Rehab Med. 2016;40(2):326-33. DOI: https://doi.org/10.5535/arm.2016.40.2.326

  21. Peltola H, Jaakkola M. C-reactive protein in early detection of bacteremia versus viral infection in inmuno-competent and compromised children. J Pediatr. 1988 Oct;113(4):641-6. DOI: https://doi.org/10.1016/s0022-3476(88)80372-x

  22. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico 2019. La Habana: MINSAP; 2020 [acceso 03/05/2020]. Disponible en: Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/año,2020

  23. San José JC, San José M. Supervivientes de cáncer: Seguimiento del linfedema. Bol Soc Esp Hidrol Med. 2017;32(1):6374. DOI: https://doi.org/10.23853/bsehm.2017.0295

  24. Rye DS, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncology. 2013;14(6):50. DOI: https://doi.org/10.1016/S1470-2045(13)70076-7.

  25. Buckley RH. Primary defects of antibody production. In: Kliegman RM, Stanton BF, St Geme JW, et al. eds. Nelson Textbook of Pediatrics. Chap 118. 20th ed. Philadelphia, PA: Elsevier; 2016 [acceso 03/07/2020]. Disponible en: Disponible en: https://clinicalgate.com/tag/nelson-textbook-of-pediatrics-expert-consult/page/13




2020     |     www.medigraphic.com